Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (20) 20
abridged index medicus (18) 18
aged (14) 14
female (13) 13
male (13) 13
medicine, general & internal (13) 13
mortality (12) 12
risk factors (12) 12
stroke (11) 11
heart attacks (10) 10
internal medicine (10) 10
middle aged (10) 10
cardiovascular disease (9) 9
clopidogrel (9) 9
acute coronary syndromes (8) 8
cardiac & cardiovascular systems (8) 8
cardiovascular diseases (8) 8
myocardial infarction (8) 8
patients (8) 8
aspirin (7) 7
prevention (7) 7
cardiology (6) 6
clinical trials (6) 6
coronary vessels (6) 6
diabetes (6) 6
disease (6) 6
hypertension (6) 6
management (6) 6
treatment outcome (6) 6
cardiovascular (5) 5
confidence intervals (5) 5
health risk assessment (5) 5
medical and health sciences (5) 5
medical colleges (5) 5
medical research (5) 5
patient outcomes (5) 5
peripheral vascular disease (5) 5
risk (5) 5
studies (5) 5
thrombosis (5) 5
anticoagulants (4) 4
atherosclerosis (4) 4
cardiac patients (4) 4
cerebral infarction (4) 4
diabetes mellitus (4) 4
double-blind method (4) 4
health risks (4) 4
heart diseases (4) 4
heart failure (4) 4
infarction (4) 4
medicin och hälsovetenskap (4) 4
medicine, experimental (4) 4
myocardial infarction - drug therapy (4) 4
myocardial-infarction (4) 4
percutaneous coronary intervention (4) 4
platelet aggregation inhibitors - therapeutic use (4) 4
risk assessment (4) 4
acute myocardial-infarction (3) 3
aged, 80 and over (3) 3
anticoagulants - therapeutic use (3) 3
antiplatelet therapy (3) 3
atherothrombosis (3) 3
blood pressure (3) 3
cardiovascular diseases - etiology (3) 3
clinical medicine (3) 3
clinical neurology (3) 3
coronary artery disease (3) 3
drug-eluting stents (3) 3
elevation myocardial-infarction (3) 3
follow-up studies (3) 3
heart attack (3) 3
hospitalization (3) 3
ischemia (3) 3
myocardial infarction - mortality (3) 3
outpatients (3) 3
platelet inhibition (3) 3
population (3) 3
prevalence (3) 3
prospective studies (3) 3
randomized controlled trials as topic (3) 3
stents (3) 3
surgery (3) 3
time factors (3) 3
veins & arteries (3) 3
adenosine monophosphate - analogs & derivatives (2) 2
adenosine monophosphate - therapeutic use (2) 2
age (2) 2
analysis (2) 2
antihypertensive agents - therapeutic use (2) 2
arteriosclerosis (2) 2
association (2) 2
atherosclerosis - complications (2) 2
bare-metal stents (2) 2
bleeding (2) 2
blood platelets (2) 2
cardiovascular diseases - mortality (2) 2
cardiovascular diseases - prevention & control (2) 2
cardiovascular events (2) 2
cerebrovascular disorders - epidemiology (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
by Costa, Francesco, MD and van Klaveren, David, MSc and James, Stefan, Prof and Heg, Dik, PhD and Räber, Lorenz, MD and Feres, Fausto, MD and Pilgrim, Thomas, MD and Hong, Myeong-Ki, Prof and Kim, Hyo-Soo, MD and Colombo, Antonio, MD and Steg, Philippe Gabriel, Prof and Zanchin, Thomas, MD and Palmerini, Tullio, MD and Wallentin, Lars, Prof and Bhatt, Deepak L, Prof and Stone, Gregg W, Prof and Windecker, Stephan, Prof and Steyerberg, Ewout W, Prof and Valgimigli, Marco, Prof and PRECISE-DAPT Study Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1025 - 1034
Summary Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IMPACT | CLOPIDOGREL | EFFICACY | BARE-METAL STENTS | RISK STRATIFICATION | GUIDELINES | ACUTE MYOCARDIAL-INFARCTION | ACUTE CORONARY SYNDROMES | DURATION | DRUG-ELUTING STENTS | Medical policy | Complications and side effects | Medical research | Medical colleges | Aspirin | Clinical trials | Medicine, Experimental | Cardiology | Medicine, Preventive | Stent (Surgery) | Preventive health services | Anticoagulants | Heart attacks | Cardiovascular disease | Hemorrhage | Thrombosis | Patients | Risk assessment | Coronary vessels | Clinical medicine | Acute coronary syndromes | Stents | Age | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
by Vidal-Petiot, Emmanuelle, MD and Ford, Ian, Prof and Greenlaw, Nicola, MSc and Ferrari, Roberto, Prof and Fox, Kim M, Prof and Tardif, Jean-Claude, Prof and Tendera, Michal, Prof and Tavazzi, Luigi, Prof and Bhatt, Deepak L, Prof and Steg, Philippe Gabriel, Prof and CLARIFY Investigators
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10056, pp. 2142 - 2152
Summary Background The optimum blood pressure target in hypertension remains debated, especially in coronary artery disease, given concerns for reduced... 
Internal Medicine | RANDOMIZED CONTROLLED-TRIALS | MEDICINE, GENERAL & INTERNAL | J-CURVE | ONGOING TELMISARTAN | METAANALYSIS | RISK | TARGETS | OUTCOMES | PREVALENCE | COMBINATION | HYPERTENSIVE PATIENTS | Blood Pressure | Stroke | Humans | Middle Aged | Hypertension - drug therapy | Male | Treatment Outcome | Coronary Artery Disease - mortality | Antihypertensive Agents - therapeutic use | Hypotension - complications | Myocardial Infarction | Hypotension - mortality | Coronary Artery Disease - complications | Female | Aged | Cohort Studies | Hypertension | Medical research | Patient outcomes | Analysis | Mortality | Cardiac patients | Medicine, Experimental | Blood pressure | France | Coronary heart disease | Cardiovascular agents | Studies | Cardiovascular disease | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
by Chakravarty, Tarun, MD and Søndergaard, Lars, Prof and Friedman, John, MD and De Backer, Ole, MD and Berman, Daniel, Prof and Kofoed, Klaus F, MD and Jilaihawi, Hasan, MD and Shiota, Takahiro, MD and Abramowitz, Yigal, MD and Jørgensen, Troels H, MD and Rami, Tanya, MS and Israr, Sharjeel, MD and Fontana, Gregory, MD and de Knegt, Martina, MD and Fuchs, Andreas, MD and Lyden, Patrick, Prof and Trento, Alfredo, Prof and Bhatt, Deepak L, Prof and Leon, Martin B, Prof and Makkar, Raj R, Prof and RESOLVE Investigator and SAVORY Investigator and SAVORY Investigators and RESOLVE
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2383 - 2392
Summary Background Subclinical leaflet thrombosis of bioprosthetic aortic valves after transcatheter valve replacement (TAVR) and surgical aortic valve... 
Internal Medicine | REPLACEMENT | MEDICINE, GENERAL & INTERNAL | STENOSIS | SCORE | IMPLANTATION | RISK | BLEEDING COMPLICATIONS | Humans | Male | Tomography, X-Ray Computed | Aortic Valve - surgery | Prosthesis Design | Four-Dimensional Computed Tomography | Thrombosis - diagnostic imaging | Aged, 80 and over | Female | Registries | Thrombosis - prevention & control | Transcatheter Aortic Valve Replacement - adverse effects | Echocardiography | Aortic Valve - diagnostic imaging | Heart Valve Prosthesis - adverse effects | Aortic Valve - physiopathology | Bioprosthesis - adverse effects | Anticoagulants - therapeutic use | Heart Valve Diseases - etiology | Heart Valve Diseases - prevention & control | Thrombosis - etiology | Aged | Prosthesis Failure - etiology | Transcatheter Aortic Valve Replacement - methods | Heart Valve Diseases - diagnostic imaging | Heart valve diseases | Thrombosis | Blood clot | Heart | Therapy | Prostheses | Demography | Funding | Heart surgery | Valves | Strokes | Clinical outcomes | Prevention | Demographics | Computed tomography | Surgery | Imaging | Tomography | Lesions | Thromboembolism | Anticoagulants | Stroke | Warfarin | Patients | Coronary vessels | Hemodynamics | Aortic valve
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
by Steg, Philippe Gabriel, Prof and Bhatt, Deepak L, Prof and Hamm, Christian W, Prof and Stone, Gregg W, MD and Gibson, C Michael, MD and Mahaffey, Kenneth W, MD and Leonardi, Sergio, MD and Liu, Tiepu, PhD and Skerjanec, Simona, PharmD and Day, Jonathan R, MD and Iwaoka, Robert S, MD and Stuckey, Thomas D, MD and Gogia, Harinder S, MD and Gruberg, Luis, MD and French, William J, MD and White, Harvey D, Prof and Harrington, Robert A, Prof and Champion Investigators and CHAMPION Investigators
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9909, pp. 1981 - 1992
Summary Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI)... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ISCHEMIC EVENTS | CLOPIDOGREL | UNIVERSAL DEFINITION | TICAGRELOR | CARDIOVASCULAR EVENTS | PLATELET INHIBITION | ASSOCIATION TASK-FORCE | PRASUGREL | ORAL ANTIPLATELET THERAPY | ELEVATION MYOCARDIAL-INFARCTION | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Adenosine Monophosphate - therapeutic use | Cause of Death | Randomized Controlled Trials as Topic | Myocardial Infarction - therapy | Graft Occlusion, Vascular - etiology | Percutaneous Coronary Intervention - methods | Adenosine Monophosphate - analogs & derivatives | Coronary Disease - therapy | Myocardial Ischemia - therapy | Acute Coronary Syndrome - therapy | Female | Myocardial Revascularization - statistics & numerical data | Aged | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Stents | Cangrelor | Drug therapy | Angioplasty | Patient outcomes | Heart attacks | Blood platelets | Coronary vessels | Acute coronary syndromes | Thrombosis | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
by Udell, Jacob A, Dr and Cavender, Matthew A, MD and Bhatt, Deepak L, Prof and Chatterjee, Saurav, MD and Farkouh, Michael E, Prof and Scirica, Benjamin M, MD
Lancet Diabetes & Endocrinology, The, ISSN 2213-8587, 2015, Volume 3, Issue 5, pp. 356 - 366
Summary Background Some glucose-lowering drugs or strategies adversely affect cardiovascular outcomes. We aimed to assess the extent to which glucose lowering... 
Endocrinology & Metabolism | Other | FASTING GLUCOSE | LIFE-STYLE INTERVENTION | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | GLYCEMIC CONTROL | INSULIN-TREATMENT | CLINICAL-TRIALS | BLOOD-GLUCOSE | ENDOCRINOLOGY & METABOLISM | ACUTE MYOCARDIAL-INFARCTION | MELLITUS | CONGESTIVE-HEART-FAILURE | Hypoglycemic Agents - therapeutic use | Heart Failure - complications | Humans | Middle Aged | Risk Factors | Aged | Diabetes Mellitus, Type 2 - drug therapy | Heart Failure - epidemiology | Hypoglycemic Agents - adverse effects | Heart Failure - chemically induced | Diabetes Mellitus, Type 2 - epidemiology | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
by Wiviott, Stephen D, Dr and White, Harvey D, Prof and Ohman, E Magnus, Prof and Fox, Keith AA, Prof and Armstrong, Paul W, Prof and Prabhakaran, Dorairaj, MD and Hafley, Gail, MS and Lokhnygina, Yuliya, PhD and Boden, William E, Prof and Hamm, Christian, Prof and Clemmensen, Peter, MD and Nicolau, Jose C, MD and Menozzi, Alberto, MD and Ruzyllo, Witold, MD and Widimsky, Petr, MD and Oto, Ali, MD and Leiva-Pons, Jose, MD and Pavlides, Gregory, MD and Winters, Kenneth J, MD and Roe, Matthew T, MD and Bhatt, Deepak L, Prof
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9892, pp. 605 - 613
Summary Background Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | 2007 GUIDELINE | PLATELET INHIBITION | RISK | ACUTE CORONARY SYNDROMES | DOSE CLOPIDOGREL | INTERVENTION | ASSOCIATION | ACCF/AHA FOCUSED UPDATE | STRATEGIES | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - mortality | Stroke - prevention & control | Ticlopidine - therapeutic use | Humans | Middle Aged | Risk Factors | Angina, Unstable - mortality | Kaplan-Meier Estimate | Acute Coronary Syndrome - mortality | Male | Treatment Outcome | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Coronary Angiography | Myocardial Infarction - drug therapy | Angina, Unstable - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Heart attacks | Medical imaging | Heart surgery | Coronary vessels | Acute coronary syndromes | Drug dosages | Patients | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?
by Curzen, Nicholas, Prof and Gurbel, Paul A, Prof and Myat, Aung, MRCP and Bhatt, Deepak L, Prof and Redwood, Simon R, Prof
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9892, pp. 633 - 643
Summary Acute ST-segment elevation myocardial infarction (STEMI) is a dynamic, thrombus-driven event. As understanding of its pathophysiology has improved, the... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | BARE-METAL STENTS | THROMBUS ASPIRATION | PLATELET INHIBITION | DOUBLE-BLIND | INTRAVENOUS BOLUS ABCIXIMAB | GLYCOPROTEIN IIB/IIIA INHIBITOR | ELEVATION MYOCARDIAL-INFARCTION | PRIMARY ANGIOPLASTY | ANTIPLATELET THERAPY | DRUG-ELUTING STENTS | Myocardial Infarction - surgery | Platelet Membrane Glycoprotein IIb - drug effects | Administration, Oral | Integrin beta3 - drug effects | Humans | Infusions, Parenteral | Anticoagulants - therapeutic use | Combined Modality Therapy | Adenosine Monophosphate - therapeutic use | Myocardial Infarction - drug therapy | Myocardial Reperfusion | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Thrombolytic Therapy | Platelet Aggregation Inhibitors - therapeutic use | Percutaneous Coronary Intervention | Acute coronary syndromes | Thrombosis | Heart attacks
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
by Zelniker, Thomas A and Wiviott, Stephen D and Raz, Itamar and Im, Kyungah and Goodrich, Erica L and Bonaca, Marc P and Mosenzon, Ofri and Kato, Eri T and Cahn, Avivit and Furtado, Remo H M and Bhatt, Deepak L and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P H and Sabatine, Marc S
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10166, pp. 31 - 39
The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | INFECTIONS | PROFILE | DAPAGLIFLOZIN | CANAGLIFLOZIN | GLUCOSE | DISEASE | COTRANSPORTER 2 INHIBITOR | MELLITUS | EMPAGLIFLOZIN | Myocardial infarction | Fees & charges | Renal function | Heart attacks | Laboratories | Clinical trials | Cardiovascular disease | Systematic review | Heterogeneity | Atherosclerosis | Data search | Cardiology | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Cerebral infarction | Stroke | Research & development--R&D | Diabetes mellitus | Mortality | Health risks | Patients | Coronary artery disease | Meta-analysis | Studies | Inhibitors | Sodium | Arteriosclerosis | Renal failure | Death | Infarction | Kidney diseases | Diabetes | Cardiovascular diseases | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The rise and fall of aspirin in the primary prevention of cardiovascular disease
by Raber, Inbar and McCarthy, Cian P and Vaduganathan, Muthiah and Bhatt, Deepak L and Wood, David A and Cleland, John G F and Blumenthal, Roger S and McEvoy, John W
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10186, pp. 2155 - 2167
Aspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By... 
MEDICINE, GENERAL & INTERNAL | LONG-TERM USE | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | RANDOMIZED-TRIAL | UNSTABLE ANGINA | CORONARY-HEART-DISEASE | COLLABORATIVE METAANALYSIS | EUROPEAN-SOCIETY | SECONDARY PREVENTION | Prevention | Medical colleges | Aspirin | Mortality | Ireland | Cardiovascular diseases | Heart attack | Myocardial infarction | Heart attacks | Physicians | Clinical trials | Cardiovascular disease | Bleeding | Cost-benefit analysis | Pain | Analgesics | Cardiology | Drug dosages | Hypertension | Cerebral infarction | Medical research | Enzymes | Stroke | Health risks | Disease prevention | Biomarkers | Diabetes | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial
by Brilakis, Emmanouil S and Edson, Robert and Bhatt, Deepak L and Goldman, Steven and Holmes, David R and Rao, Sunil V and Rao, Sunil and Shunk, Kendrick and Rangan, Bavana V and Mavromatis, Kreton and Ramanathan, Kodangudi and Bavry, Anthony A and Bavry, Anthony and Garcia, Santiago and Latif, Faisal and Armstrong, Ehrin and Jneid, Hani and Conner, Todd A and Wagner, Todd and Karacsonyi, Judit and Uyeda, Lauren and Ventura, Beverly and Alsleben, Aaron and Lu, Ying and Lu, David and Shih, Mei-Chiung and Banerjee, Subhash and Ahmed, Zubair and Ahmed, Bina and Ratliff, D Michelle and Ricciardi, Mark and Sheldon, Mark and Icenogle, Milton and Snider, Richard and Ardati, Amer and Nallamothu, Brahmajee and Duvernoy, Claire and Menees, Daniel S and Gurm, Hitinder and Thomas, Michael P and Grossman, Paul and Owen, Kristine and Topaz, On and Kumar, Gautam and Kumar, Arun and Block, Peter and Zidar, David A and Bezerra, Hiram and Goldberg, Jonathan and Ortiz, Jose and Jozic, Joseph and Osman, Mohammed and Rosenthal, Noah and Parikh, Sahil A and Lassar, Tom A and Chan, Albert and Aggarwal, Kul and Cyrus, Tillmann and Grodin, Jerrold and Hattler, Brack and Casserly, Ivan and Messenger, John and Kim, Michael and Rogers, R Kevin and Waldo, Stephen and Tsai, Thomas and Morris, Kenneth and Krucoff, Mitchell and Povsic, Thomas J and Jones, William S and Choi, Calvin and Park, Ki and Liu, MD, Jayson and Kar, Biswajit and Paniagua, David and Breall, Jeffrey and Bolad, Islam and Mukerji, Rita and Subbarao, Roopa and Abdel-Latif, Ahmed and Booth, David C and Ziada, Khaled M and Rajan, Lawrence and Hakeem, Abdul and Uretsky, Barry F and Agrawal, Mayank and Sachdeva, Rajesh and McGee, Jesse and Shah, Rahman and Sharma, Alok and McFalls, Edward and Siddiqui, Rizwan and Adabag, Selcuk and Bertog, Stefan and Irimpen, Anand and Baldwin, Drew and Abi Rafeh, Nidal and Mogabgab, Owen and Delafontaine, Patrice and Lorin, Jeffrey and ... and DIVA Trial Investigators
The Lancet, ISSN 0140-6736, 05/2018, Volume 391, Issue 10134, pp. 1997 - 2007
Few studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with... 
SURGERY | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | CLINICAL IMPACT | COMPETING RISK | IMPLANTATION | PREDICTORS | NATIVE CORONARY | FOLLOW-UP | BYPASS GRAFTS | LESIONS | Graft Rejection - drug therapy | Drug-Eluting Stents | Double-Blind Method | Humans | Middle Aged | Male | Thrombosis - epidemiology | Treatment Outcome | Saphenous Vein - surgery | Self Expandable Metallic Stents | Percutaneous Coronary Intervention - instrumentation | Thrombosis - etiology | Female | Aged | Clinical trials | Myocardial infarction | Intervention | Surgical implants | Heart attacks | Laboratories | Physicians | Metals | Stenosis | Drug delivery | Incidence | Cost-benefit analysis | Randomization | Implants | Lesions | Thromboembolism | Heart diseases | Stents | Medical personnel | Research & development--R&D | Diabetes mellitus | Patients | Thrombosis | Studies | Government agencies | Grafts | Coronary vessels | Federal agencies | Infarction | Acute coronary syndromes | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights